Changeflow GovPing Healthcare & Life Sciences Bayer HealthCare Patent Term Extension Exhibits...
Routine Notice Added Final

Bayer HealthCare Patent Term Extension Exhibits D-G

Email

Summary

Bayer HealthCare submitted exhibits D-G to FDA in connection with a patent term extension application under docket FDA-2026-E-4532. The exhibits constitute supporting documentation for the extension request and have been filed in the regulatory docket for public access. No FDA action or determination is reflected in this filing.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

Every FDA document on regulations.gov, the federal rulemaking portal. This is where the agency posts variances, advisory committee meeting notices, draft guidance for comment, citizen petition responses, and procedural rules that do not get a separate Federal Register slot. Around 240 a month. FDA's heavy regulations.gov use means tracking only the Federal Register misses a meaningful chunk of what the agency does day-to-day. Watch this if you manufacture devices, submit IND or NDA applications, run a lab, or advise sponsors on FDA process. GovPing publishes each posting with the docket, document type, division (CDER, CDRH, CFSAN), and comment window where one applies.

What changed

Bayer HealthCare filed exhibits D-G with FDA as part of a patent term extension application. The exhibits represent supporting materials for the extension request and have been formally entered into the regulatory record. This is a submission document, not an FDA action or determination.

Affected parties submitting patent term extension applications to FDA should ensure all required exhibits are filed in the correct docket format. Competitors monitoring patent expiration timelines should review filed exhibits for information that may affect their product launch planning.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-E-4532

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent term extension Regulatory filing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!